<DOC>
	<DOC>NCT00877539</DOC>
	<brief_summary>PF-03526299, a novel anti-inflammatory agent should attenuate the effect of a bronchial allergen challenge on lung function and hence provide proof of mechanism for this agent.</brief_summary>
	<brief_title>A Study To Assess The Effect Of PF-03526299 On Lung Function Following An Allergen Challenge In Asthmatic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Males and females 1860 years Mild asthma Atopic to allergens Unstable asthma Smokers or recent exsmokers Recent allergen challenge</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Asthma Allergen Challenge</keyword>
</DOC>